Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Dendritic cells (DC) have been successfully used in clinical pilot studies to induce tumor-specific immunity as well as clinical response in selected patients. However, DC-based immunotherapy remains a challenge and several parameters need to be examined in order to optimize the induction of anti-tumor immune responses. This study focuses on DC vaccination for leukemia and evaluates the in vitro efficacy of three different strategies for generating antigen-loaded DC-based vaccines for the induction of major histocompatibility complex (MHC) class I-restricted anti-leukemia cytotoxic T lymphocyte (CTL) responses. These included direct fusion of DC with leukemia cells to generate DC-leukemia cell hybrids, and DC pulsed with either apoptotic leukemia cell fragments or whole tumor cell lysates. Using either the U937 cell line or primary human acute myeloid leukemia blasts (AML), DC-leukemia cell hybrids were found to be the most potent in vitro inducers of CTL activity. DC pulsed with apoptotic tumor cell fragments were less efficient, but induced a more potent CTL response compared to tumor lysate-pulsed DC. The CTL responses were both MHC class I-restricted and antigen-specific, as shown by the inability of the CTL to lyse other control targets. The data presented here suggest that the method of antigen loading onto DC may be critical in the design of tumor vaccines.

Original publication

DOI

10.1007/s00262-002-0284-4

Type

Journal article

Journal

Cancer Immunol Immunother

Publication Date

08/2002

Volume

51

Pages

299 - 310

Keywords

Antigen Presentation, Antigens, Neoplasm, Cancer Vaccines, Cell Count, Cell Differentiation, Cell Fusion, Culture Media, Conditioned, Dendritic Cells, Histocompatibility Antigens Class I, Humans, Hybrid Cells, Immunophenotyping, K562 Cells, Leukemia, Myeloid, Acute, Lymphocyte Activation, Monocytes, Neoplastic Stem Cells, Phagocytosis, T-Lymphocytes, Cytotoxic, U937 Cells